It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Plaque psoriasis in children and adolescents – the role of etane
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14832

Plaque psoriasis in children and adolescents – the role of etanercept



Review

(2227) Total Article Views


Authors: Ricceri F, Tripo L, Pescitelli L, Prignano F

Published Date June 2012 Volume 2012:2 Pages 25 - 28
DOI: http://dx.doi.org/10.2147/PTT.S26032

Received: 12 April 2012
Accepted: 07 May 2012
Published: 11 June 2012
Federica Ricceri, Lara Tripo, Leonardo Pescitelli, Francesca Prignano

Division of Clinical, Preventive and Oncology Dermatology, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy

Background: Childhood-onset psoriasis affects approximately one-third of the psoriatic population. Among many potential treatments of childhood psoriasis, biological agents are emerging as a valuable option in the management of this disease. In Europe, etanercept has recently been approved for children aged 6 years and over. Data from a well-designed clinical trial indicate that in children, etanercept effectively reduces psoriasis symptoms, with beneficial effects evident as early as 4 weeks after the onset of therapy. The treatment is generally well tolerated; mild injection site reactions are the most common adverse events reported in the literature. Published data of etanercept use in children show promising results, but further clinical studies are necessary to confirm its long-term efficacy and safety.

Keywords: pediatric psoriasis, anti-TNF-α, etanercept



Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read: